A number of other research firms have also commented on LXRX. Gabelli raised Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $3.00 price target on the stock in a research report on Wednesday, September 11th. Citigroup lowered Lexicon Pharmaceuticals from a buy rating to a neutral rating and boosted their price objective for the company from $3.00 to $4.00 in a research report on Friday, November 8th. Zacks Investment Research cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, November 16th. G.Research raised Lexicon Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, September 11th. Finally, ValuEngine upgraded shares of Lexicon Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $6.45.
LXRX opened at $4.87 on Friday. The stock has a market cap of $449.53 million, a P/E ratio of 3.11 and a beta of 1.00. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $8.39. The company has a quick ratio of 8.01, a current ratio of 8.11 and a debt-to-equity ratio of 1.42. The company has a fifty day simple moving average of $3.68 and a 200 day simple moving average of $3.86.
In other news, Director Christopher J. Sobecki purchased 99,249 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 13th. The stock was purchased at an average price of $2.41 per share, with a total value of $239,190.09. Following the transaction, the director now directly owns 13,645 shares in the company, valued at approximately $32,884.45. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were acquired at an average cost of $2.55 per share, with a total value of $63,750.00. Following the completion of the purchase, the director now directly owns 112,493 shares in the company, valued at $286,857.15. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 178,749 shares of company stock valued at $474,560. Company insiders own 6.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Quantitative Systematic Strategies LLC boosted its holdings in Lexicon Pharmaceuticals by 67.2% during the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 8,302 shares during the last quarter. Wedbush Securities Inc. lifted its position in Lexicon Pharmaceuticals by 33.0% during the 2nd quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock worth $1,222,000 after buying an additional 48,182 shares in the last quarter. Swiss National Bank lifted its position in Lexicon Pharmaceuticals by 18.3% during the 2nd quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 13,700 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Lexicon Pharmaceuticals by 217.5% during the 2nd quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock worth $548,000 after buying an additional 59,685 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $92,000. 96.27% of the stock is currently owned by institutional investors and hedge funds.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: Why is cost of goods sold important?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.